ATE533858T1 - Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatin - Google Patents
Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatinInfo
- Publication number
- ATE533858T1 ATE533858T1 AT06707630T AT06707630T ATE533858T1 AT E533858 T1 ATE533858 T1 AT E533858T1 AT 06707630 T AT06707630 T AT 06707630T AT 06707630 T AT06707630 T AT 06707630T AT E533858 T1 ATE533858 T1 AT E533858T1
- Authority
- AT
- Austria
- Prior art keywords
- carboplatin
- cisplatin
- clinical response
- chemotherapeutic treatment
- predicting clinical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2523/00—Reactions characterised by treatment of reaction samples
- C12Q2523/10—Characterised by chemical treatment
- C12Q2523/125—Bisulfite(s)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/154—Methylation markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05075632A EP1702989A1 (de) | 2005-03-16 | 2005-03-16 | Verfahren zur Vorhersage der klinischen Reaktion auf die chemotherapeutische Behandlung mit Cisplatin oder Carboplatin |
PCT/EP2006/002610 WO2006097346A1 (en) | 2005-03-16 | 2006-03-16 | Method of predicting the clinical response to platinum based chemotherapeutic treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE533858T1 true ATE533858T1 (de) | 2011-12-15 |
Family
ID=34938100
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06707630T ATE533858T1 (de) | 2005-03-16 | 2006-03-16 | Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatin |
Country Status (9)
Country | Link |
---|---|
US (1) | US8377888B2 (de) |
EP (2) | EP1702989A1 (de) |
JP (1) | JP4954970B2 (de) |
AT (1) | ATE533858T1 (de) |
CA (1) | CA2601145A1 (de) |
DK (1) | DK1863925T3 (de) |
ES (1) | ES2380117T3 (de) |
HK (1) | HK1116518A1 (de) |
WO (1) | WO2006097346A1 (de) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015154064A2 (en) | 2014-04-04 | 2015-10-08 | Del Mar Pharmaceuticals | Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6756200B2 (en) * | 2001-01-26 | 2004-06-29 | The Johns Hopkins University School Of Medicine | Aberrantly methylated genes as markers of breast malignancy |
DE10161625A1 (de) * | 2001-12-14 | 2003-07-10 | Epigenomics Ag | Verfahren und Nukleinsäuren für die Analyse einer Lungenzell-Zellteilungsstörung |
KR100470221B1 (ko) * | 2002-02-20 | 2005-02-05 | 굿젠 주식회사 | 유전자 프로모터 CpG 아일랜드의 메틸화 여부를분석하는 염기서열분석형 올리고뉴클레오타이드칩, 이의제조방법 및 이를 이용한 암 검색방법 |
JP2007501002A (ja) * | 2003-08-01 | 2007-01-25 | ザ ユニバーシティ オブ ウェスタン オーストラリア | 癌治療の成功の可能性を予測するための方法及びキット |
EP1692255A4 (de) * | 2003-11-12 | 2010-12-08 | Univ Boston | Isolierung von nukleinsäure aus mundepithelzellen |
-
2005
- 2005-03-16 EP EP05075632A patent/EP1702989A1/de not_active Withdrawn
-
2006
- 2006-03-16 JP JP2008501244A patent/JP4954970B2/ja not_active Expired - Fee Related
- 2006-03-16 AT AT06707630T patent/ATE533858T1/de active
- 2006-03-16 US US11/908,796 patent/US8377888B2/en not_active Expired - Fee Related
- 2006-03-16 CA CA002601145A patent/CA2601145A1/en not_active Abandoned
- 2006-03-16 DK DK06707630.7T patent/DK1863925T3/da active
- 2006-03-16 EP EP06707630A patent/EP1863925B1/de not_active Not-in-force
- 2006-03-16 ES ES06707630T patent/ES2380117T3/es active Active
- 2006-03-16 WO PCT/EP2006/002610 patent/WO2006097346A1/en active Application Filing
-
2008
- 2008-06-12 HK HK08106539.7A patent/HK1116518A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP1702989A1 (de) | 2006-09-20 |
EP1863925B1 (de) | 2011-11-16 |
US20090068657A1 (en) | 2009-03-12 |
CA2601145A1 (en) | 2006-09-21 |
JP4954970B2 (ja) | 2012-06-20 |
EP1863925A1 (de) | 2007-12-12 |
WO2006097346A1 (en) | 2006-09-21 |
US8377888B2 (en) | 2013-02-19 |
JP2008532531A (ja) | 2008-08-21 |
ES2380117T3 (es) | 2012-05-08 |
DK1863925T3 (da) | 2012-03-12 |
HK1116518A1 (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kim et al. | Chemoresistance evolution in triple-negative breast cancer delineated by single-cell sequencing | |
WO2005098445A3 (en) | Lung cancer biomarkers | |
EP2392678A3 (de) | Prognosevorhersage für Kolorektalkrebs | |
ATE496142T1 (de) | Verfahren zur diagnose von nicht-kleinzelligem lungenkrebs | |
Fiskaa et al. | Distinct small RNA signatures in extracellular vesicles derived from breast cancer cell lines | |
BRPI0612169A2 (pt) | métodos prognósticos, métodos de detecção, de distinção, de identificação, de determinação e de monitoramento relacionados com cáncer de pulmão, métodos para amplificação de um ácido nucléico que codifica c-met humano , biomarcadores de cáncer de pulmão, agentes de imagem de cáncer de pulmão, polinucleotìdeos, agente s de ligação de antìgeno, conjuntos, meios legìveis em computador e kits e/ou artigos de fabricação | |
ATE548469T1 (de) | Verfahren zur identifizierung mehrerer mutationen oder methylierungsmarkern in einem dominierenden hintergrund von wildtyp-dna | |
ATE531725T1 (de) | Verfahren zur vorhersage ob nsclc-patienten auf eine behandlung mit einem egfr-tk-hemmer ansprechen | |
WO2007087612A8 (en) | Detection and diagnosis of smoking related cancers | |
Shah et al. | Occupational exposures and odds of gastric cancer: a StoP project consortium pooled analysis | |
BRPI0607507A2 (pt) | método in vitro para a identificação de compostos para tratamento do cáncer | |
DE602004015626D1 (de) | Bei brustkrebs | |
ATE479095T1 (de) | Prozess und reagenzien für extraktion von rns von fraktionierten blutleukozyten | |
Sureshchandra et al. | Chronic heavy drinking drives distinct transcriptional and epigenetic changes in splenic macrophages | |
Leahy et al. | Interleukin-15 is associated with disease severity in viral bronchiolitis | |
Park et al. | Incidence, clinical features, and prognostic impact of CALR exon 9 mutations in essential thrombocythemia and primary myelofibrosis: an experience of a single tertiary hospital in Korea | |
ATE533858T1 (de) | Verfahren zur vorhersage der klinischen reaktion auf die chemotherapeutische behandlung mit cisplatin oder carboplatin | |
Wong et al. | Targeting general transcriptional machinery as a therapeutic strategy for adult T-cell leukemia | |
WO2012054824A3 (en) | Prognostic biomarkers in patients with ovarian cancer | |
Savage et al. | The impact of concurrent MYC BCL2 protein expression on the risk of secondary central nervous system relapse in diffuse large B-cell lymphoma (DLBCL) | |
Chen et al. | Genetic polymorphisms of the glycine N-methyltransferase and prostate cancer risk in the health professionals follow-up study | |
WO2008086800A3 (en) | Predisposition to, prognosis for and treatment of breast cancer relating to human chromosome 16 | |
DE112007003223A5 (de) | Prognostische Marker für die Klassifizierung des dreijährigen progressionsfreien Überlebens von Patienten mit kolorektalem Karzinom basierend auf Expressionsprofilen von biologischen Proben | |
Wilson et al. | An in vitro quantitative systems pharmacology approach for deconvolving mechanisms of drug-induced, multilineage cytopenias | |
Khojah et al. | Extracellular RNA signatures of mutant KRAS (G12C) lung adenocarcinoma cells |